Market closedNon-fractional
Johnson & Johnson/JNJ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Johnson & Johnson
Ticker
JNJ
Sector
Healthcare
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
New Brunswick, United States
Employees
131,900
Website
www.jnj.com
JNJ Metrics
BasicAdvanced
$384B
Market cap
10.33
P/E ratio
$15.45
EPS
-
Beta
$4.81
Dividend rate
3.01%
Dividend yield
Price and volume
Market cap
$384B
Dividend rate
$4.81
Financial strength
Total debt to equity
48.032
Interest coverage (TTM)
31.38%
Management effectiveness
Valuation
Price to earnings (TTM)
10.332
Price to revenue (TTM)
4.485
Price to book
5.49
Price to tangible book (TTM)
-435.55
Dividend yield (TTM)
3.01%
Growth
Revenue change (TTM)
-11.02%
Earnings per share change (TTM)
213.48%
3-year revenue growth (CAGR)
-0.99%
3-year earnings per share growth (CAGR)
32.44%
3-year dividend per share growth (CAGR)
5.55%
What the Analysts think about JNJ
Analyst Ratings
Majority rating from 25 analysts.
JNJ Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$21B
-0.06%
Net income
$3.3B
-19.61%
Profit margin
15.22%
-19.56%
JNJ Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$2.80
$2.66
$2.29
$2.71
-
Expected
$2.62
$2.52
$2.28
$2.64
$2.71
Surprise
7.02%
5.73%
0.40%
2.76%
-
JNJ News
AllArticlesVideos
Top 10 Dividend Stocks For A Recession-Focused Portfolio In 2024
Seeking Alpha·7 hours ago
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
Business Wire·11 hours ago
![Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fe%2F8%2Fpress6-2547761.jpg&w=3840&q=75)
Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
GlobeNewsWire·13 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
Aug
27
Johnson & Johnson
Dividend·Ex-dividend
Sept
10
Johnson & Johnson
Dividend·Payment
$1.24
Per share
FAQs
What’s the current market cap for Johnson & Johnson stock?
Johnson & Johnson (JNJ) has a market cap of $384B as of July 27, 2024.
What is the P/E ratio for Johnson & Johnson stock?
The price to earnings (P/E) ratio for Johnson & Johnson (JNJ) stock is 10.33 as of July 27, 2024.
Does Johnson & Johnson stock pay dividends?
Yes, the Johnson & Johnson (JNJ) stock pays dividends to shareholders. As of July 27, 2024, the dividend rate is $4.81 and the yield is 3.01%. Johnson & Johnson has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Johnson & Johnson dividend payment date?
The next Johnson & Johnson (JNJ) dividend payment is scheduled for September 10, 2024.
What is the beta indicator for Johnson & Johnson?
Johnson & Johnson (JNJ) does not currently have a Beta indicator.
Buy or sell Johnson & Johnson stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.